Skip to main content
Clinical Trials/NCT05764642
NCT05764642
Enrolling by Invitation
Phase 2

Renal Microvessel Imaging for Characterization of Chronic Kidney Disease

Mayo Clinic2 sites in 1 country186 target enrollmentAugust 9, 2023

Overview

Phase
Phase 2
Intervention
Definity
Conditions
Healthy
Sponsor
Mayo Clinic
Enrollment
186
Locations
2
Primary Endpoint
Renal cortex microvessel diameter
Status
Enrolling by Invitation
Last Updated
7 months ago

Overview

Brief Summary

The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.

Registry
clinicaltrials.gov
Start Date
August 9, 2023
End Date
April 1, 2028
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Shigao Chen

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • \- Healthy volunteers or Chronic Kidney Disease (CKD) patients with clinically indicated renal biopsy.

Exclusion Criteria

  • Subjects lacking capacity to consent.
  • Vulnerable subjects such as prisoners; pregnant women; nursing mother.
  • Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents.
  • Patients with high-risk cardiac diseases.

Arms & Interventions

Chronic Kidney Disease Group

Subjects with Chronic Kidney Disease (CKD) with clinically indicated renal biopsy will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

Intervention: Definity

Chronic Kidney Disease Group

Subjects with Chronic Kidney Disease (CKD) with clinically indicated renal biopsy will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

Intervention: Super-resolution ultrasound imaging

Healthy Control Group

Healthy volunteers with normal eGFR will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

Intervention: Definity

Healthy Control Group

Healthy volunteers with normal eGFR will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

Intervention: Super-resolution ultrasound imaging

Outcomes

Primary Outcomes

Renal cortex microvessel diameter

Time Frame: Baseline

Super-Resolution Ultrasound Imaging (SRUI) parameters reported in millimeters (mm)

Renal blood flow velocity

Time Frame: Baseline

Super-Resolution Ultrasound Imaging (SRUI) parameters reported in centimeters per second (cm/sec)

Renal cortex microvessel density

Time Frame: Baseline

Super-Resolution Ultrasound Imaging (SRUI) parameters reported in percentage

Study Sites (2)

Loading locations...

Similar Trials